Table 2.

Comparison of modified Rodnan Skin Score (mRSS) in Scleroderma Lung Study (SLS)- I (placebo) vs. SLS-I (CYC), SLS-II (CYC+MMF pooled) and SLS-II (MMF) in diffuse cutaneous systemic sclerosis at 12 months utilizing minimum clinically important difference (MCID) which is defined as ≥ 5units improvement and ≥ 5units worsening in mRSS.

	N	mRSS improvement (≥5.0 units)(%)	mRSS worsening (≥5.0 units)(%)	mRSS change between −5.0 and +5.0, %
SLS-I (Placebo group)	63	25%	16%	59%
SLS-I (CYC group)	68	40%	7%	53%
SLS-II (pooled group)	113	37%	4%	59%
SLS-II (MMF group)	58	38%	4%	59%